Chilean Cobalt names Lawrence Snee as EVP of Exploration

Chilean Cobalt Corp. (OTCQB: COBA) is pleased to announce the appointment of Dr. Lawrence W. Snee as its new Executive Vice President of Exploration.

In this role, Dr. Snee is expected to be a key member of the leadership team, responsible for developing and executing Chilean Cobalt's exploration activities, leading efforts from generative greenfield to advanced-stage exploration, and near-mine resource expansion, while contributing to the overall corporate strategic plan.

Dr. Snee has served as a Technical Advisor at Chilean Cobalt since November 2023. He is a Certified Professional Geologist and Qualified Person with over 40 years of global experience as a specialist in field geology, mineral resources, petrology, geochemistry, isotope geology, structural geology, tectonics, economic geology, and the geology of world gemstone deposits. Dr. Snee previously served as Geological Director for John T. Boyd Company, Exploration Manager for Crest International Investments, and VP of Exploration and Executive Director for Central Asian Minerals and Resources. From 1974 to 2006, he was a Research Scientist and Team Chief Scientist at the US Geological Survey (USGS), where he was a manager of over 100 scientists, technicians, and administrative personnel, including serving as the Chief Scientist for the National Cooperative Geologic Mapping Team in Lakewood, CO. Dr. Snee has over 300 publications covering a wide range of geologic subjects. He has done geological consulting in the U.S., Afghanistan, Tajikistan, Egypt, Chile, China, Colombia, Guatemala, Brazil, Mexico, and southeastern Europe. He has supervised more than 50 graduate students, both U.S. and foreign, and he has hosted two Fulbright Fellows from Pakistan.

Dr. Snee holds a PhD and MS in Geology from The Ohio State University and a BS in Geology, Biology, and Chemistry from Florida State University.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• CoVolt Power files for proposed IPO
• enVVeno Medical (NVNO) files $100M mixed shelf